BioSpace News Archive

Bureau Veritas, a world-leader in testing, inspection, and certification (TIC) services, today announced it has met rigorous ISO 17025 standards to become the first Canadian laboratory to receive accreditation for eDNA testing from the Standards Council of Canada.

PER® Global, a worldwide leading resource for continuing medical education (CME), will host the live CME-accredited Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies, adjunct to the IASLC 2019 World Conference on Lung Cancer.

Conagen, a vertically integrated synthetic biology company located in Boston’s biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).

Enable Injections, Inc. (Enable), a company developing and manufacturing investigational wearable infusion devices for combination products, today announced it has entered into a development agreement with Genentech, a member of the Roche Group.

Jetson, the world’s first seasonal probiotic, welcomes Dr. Ian K. Smith MD, a respected physician and #1 New York Times best-selling author, in the newly created role of Chief Medical Advisor

Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast Cancer Conference Expert Panel has recommended the Oncotype DX Breast Recurrence Score® test to guide chemotherapy treatment use for patients with hormone-receptor positive,

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet.